Xyzal M Kid (DT) Tablet is a pediatric formulation combining Levocetirizine 2.5 mg and Montelukast 4 mg, designed to provide effective relief from allergic conditions in children. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms such as sneezing, nasal congestion, rhinorrhea, and itching associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, blocks leukotriene D4 at the cysteinyl leukotriene receptor, mitigating airway inflammation and bronchoconstriction commonly observed in asthma and allergic rhinitis. The combination of these agents offers a dual mechanism of action, targeting both histamine-mediated and leukotriene-mediated pathways, resulting in comprehensive symptom control. Xyzal M Kid (DT) is formulated as a dispersible tablet to facilitate ease of administration in pediatric patients, enhancing compliance. It is indicated for the treatment of allergic rhinitis, chronic urticaria, and mild to moderate asthma in children. The safety profile is favorable, with minimal sedation and gastrointestinal adverse effects reported. Dosage should be as prescribed by a healthcare professional, considering the child’s age and clinical condition. This combination therapy provides an effective and convenient option for managing pediatric allergic disorders.